Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Stomach and esophageal cancer
ONO-4578 (EP4/PGE2-axis antagonist) + nivolumab + oxaliplatin chemo improves PFS in 1L HER2-negative gastric/GEJ cancer
ONO-4578 is an oral, selective EP4 antagonist designed to blunt PGE2-driven tumor immunosuppression and potentially deepen anti–PD-1 activity when combined with nivolumab. In this multicenter, double-blind,…
- Trial result Spotlight
Neuroendocrine and adrenal tumors
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs
¹⁷⁷Lu-DOTATATE is a radiolabeled somatostatin analog (PRRT) that targets somatostatin receptor–positive (SSTR+) disease; in the open-label, randomized Phase 3 NETTER-2 trial (NCT03972488), previously untreated…
NCT03972488 - New trial Spotlight
Stomach and esophageal cancer
Phase 3 cadonilimab PD-1×CTLA-4 bispecific antibody + CAPOX vs CAPOX ± nivolumab in 1L HER2-negative gastric/GEJ
Akeso’s randomized, double-blind, multi-regional Phase 3 trial (NCT07700979) tests whether adding cadonilimab—a PD-1 (CD279) and CTLA-4 dual-targeting bispecific antibody—improves overall survival versus a control…
NCT07700979 Registrational - New trial Spotlight
Liver and bile duct cancer
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC
Single-arm Phase 2 at the University of Alabama at Birmingham evaluates zolbetuximab, a CLDN18.2-targeted monoclonal antibody that can drive tumor cell killing via immune effector mechanisms (including ADCC and…
NCT07723534 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2 ARV-6723 oral PROTAC HPK1 degrader ± pembrolizumab (PD-1 mAb) in solid tumors
This first-in-human, open-label Phase 1/2 study sponsored by Arvinas evaluates ARV-6723 as monotherapy and combined with pembrolizumab (Merck/MSD’s anti–PD-1 monoclonal antibody) in adults with advanced/metastatic,…
NCT07749586 First-in-human - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + BR delivers 96% CR and 83% 3-year PFS in 1L follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody; in EPCORE NHL-2 arm 3 (Phase 1b/2; NCT04663347), it was combined with first-line bendamustine+rituximab (BR) followed by epcoritamab…
NCT04663347 - New trial Spotlight
Prostate cancer
Phase 1 FX-111 ARON degrader targets transcriptionally active androgen receptor in mCRPC.
This Phase 1, first-in-human, open-label dose-escalation with optional expansion study evaluates FX-111 in adult men with metastatic castration-resistant prostate adenocarcinoma that has progressed on…
NCT07719361 First-in-human - New trial Spotlight
Colorectal cancer
Phase 2 botensilimab CTLA-4 antibody + balstilimab PD-1 antibody in early MSS rectal cancer.
This prospective, multi-site, non-randomized Phase 2 study (RECTIFY-1) tests neoadjuvant dual-checkpoint blockade in early, resectable rectal adenocarcinoma that is microsatellite stable / mismatch repair proficient…
NCT07735624 Exploratory - New trial Spotlight
Lymphoma
Phase 2/3 MK-1045 CD19×CD3 bispecific antibody plus rituximab (CD20 mAb) in 1L FL.
Merck Sharp & Dohme (MSD) is running a Phase 2/3, randomized, open-label study testing MK-1045 + rituximab (or a rituximab biosimilar) versus physician’s choice chemoimmunotherapy in previously untreated classical…
NCT07634471 Registrational - New trial Spotlight
Multiple solid tumors
Phase 1/2 CS2009 PD-1/VEGFA/CTLA-4 trispecific antibody in advanced solid tumors
This first-in-human, open-label, multicenter Phase 1/2 study evaluates CS2009, CStone Pharmaceuticals’ trispecific monoclonal antibody designed to block PD-1 (reinvigorates exhausted T cells), CTLA-4 (promotes T-cell…
NCT06741644 First-in-human - Trial result Spotlight
Multiple myeloma
Teclistamab (BCMA×CD3 bispecific) drives 76.9% ORR and 25.1-mo mPFS in TCE-RRMM (China)
Teclistamab is a subcutaneous BCMA×CD3 T-cell–redirecting bispecific antibody evaluated in the MajesTEC-1 China cohort with 27.2 months’ follow-up in triple-class exposed RRMM (n=26), dosed 1.5mg/kg weekly with an…
NCT03145181 - Trial result Spotlight
Lymphoma
Liso-cel (CD19 CAR-T) sustains 68% 3-year PFS in 3L+ follicular lymphoma
Lisocabtagene maraleucel (liso-cel) is an autologous anti-CD19 CAR-T cell therapy evaluated in the Phase 2 TRANSCEND FL study in relapsed/refractory follicular lymphoma after ≥2 prior systemic regimens including…
NCT04245839 - Trial result Spotlight
Acute lymphoblastic leukemia
Blinatumomab (CD19×CD3 BiTE) consolidation cuts relapse in high-risk Ph− adult B‑ALL (5‑yr CIR 23% vs 49%)
Blinatumomab is a CD19×CD3 bispecific T‑cell engager given here as an immunotherapy “overlay” on intensive chemotherapy, tested in the Phase 2 GRAALL‑2014/B‑QUEST substudy in newly diagnosed high-risk (KMT2A‑r, IKZF1…
NCT03709719 - Trial result Spotlight
Breast cancer
Camizestrant (oral SERD) + CDK4/6i doubles PFS when ctDNA ESR1 mutations emerge on 1L AI
Camizestrant (AZD9833) is an oral selective estrogen receptor degrader (SERD) designed to antagonize and degrade ER, including mutant ER, and in SERENA-6 (Phase 3, double-blind) it was used as an early “molecular…
NCT04964934 - Trial result Spotlight
Lymphoma
Nivolumab (PD-1) + AVD lifts 3-year PFS in EBV+ and non–nodular sclerosis advanced cHL vs BV-AVD
Nivolumab-AVD (N-AVD) combines PD-1 blockade (nivolumab) with doxorubicin/vinblastine/dacarbazine chemotherapy, and in the Phase 3 SWOG S1826 frontline trial in stage III–IV classic Hodgkin lymphoma (NCT03907488),…
NCT03907488 - Trial result Spotlight
Kidney cancer
Panitumumab-based EGFR blockade drives 53.9% ORR in platinum-refractory renal medullary carcinoma
SMARCB1-deficient renal medullary carcinoma (RMC)—a rare, hypoxic medullary kidney cancer enriched in young patients of African descent with sickle cell trait—was historically treated with platinum-based chemotherapy…
NCT06444880 - Trial result Spotlight
Bladder and urothelial cancer
Cretostimogene grenadenorepvec (RB–E2F–selective oncolytic virus) drives 75% CR with near-zero severe toxicity in BCG-unresponsive CIS NMIBC
Cretostimogene grenadenorepvec is an intravesical, replication-competent oncolytic immunotherapy that preferentially replicates in and lyses tumor cells with retinoblastoma–E2F pathway alterations while also boosting…
NCT04452591 - Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) lifts EFS/OS vs cisplatin-gemcitabine in MIBC
Enfortumab vedotin is a Nectin-4–directed antibody–drug conjugate (MMAE payload) and pembrolizumab is a PD-1 inhibitor; in the Phase 3, open-label KEYNOTE-B15/EV-304 trial (NCT04700124), cisplatin-eligible…
NCT04700124 - Trial result Spotlight
Thyroid cancer
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer
Dabrafenib, a BRAF inhibitor, plus the MEK inhibitor trametinib was tested in a global, randomized, double-blind Phase 3 trial (NCT04940052) in previously treated, radioactive iodine–refractory BRAF V600E–positive…
NCT04940052 - Trial result Spotlight
Multiple solid tumors
Erdafitinib (pan-FGFR TKI) drives 56% ORR in FGFR-altered pancreatic cancer in RAGNAR
Erdafitinib is an oral pan-FGFR1–4 tyrosine kinase inhibitor (TKI) tested in the Phase 2, histology-agnostic RAGNAR trial (NCT04083976) in patients with advanced/unresectable/metastatic solid tumors and FGFR…
NCT04083976 - New trial Spotlight
Ovarian cancer
Phase 3 rinatabart sesutecan (Rina-S) FRα ADC delivering exatecan (topoisomerase I inhibitor)
Genmab’s open-label, randomized Phase 3 trial (NCT07564141; ~688 participants planned) tests rinatabart sesutecan (Rina-S)—a folate receptor alpha (FRα/FOLR1)–directed antibody-drug conjugate that delivers an…
NCT07564141 Registrational - New trial Spotlight
Cervical and other gynecologic cancers
Phase 2 tisotumab vedotin (tissue factor–targeted) MMAE ADC in recurrent/metastatic vulvar SCC.
This open-label, single-arm Phase 2 study sponsored by the GOG Foundation evaluates tisotumab vedotin in recurrent or metastatic vulvar squamous cell carcinoma, with objective response rate as the primary efficacy…
NCT07672782 Exploratory - Trial result Spotlight
Acute lymphoblastic leukemia
Memory-enriched CD19 CAR-T delivers 84% 18-mo EFS in older CR1 B-ALL
Memory-enriched autologous CD19 CAR-T cells are engineered to target CD19 and were tested as “definitive consolidation” after remission rather than as salvage therapy. In a Phase 1 study in older adults with B-cell…
NCT05707273 - Trial result Spotlight
Chronic lymphocytic leukemia
Pirtobrutinib (non-covalent BTK inhibitor) + venetoclax-rituximab lifts PFS vs VR in relapsed CLL/SLL
Pirtobrutinib (LOXO-305; a reversible/non-covalent BTK inhibitor) was added to fixed-duration venetoclax (BCL2 inhibitor) + rituximab (anti-CD20) in BRUIN CLL-322, an open-label, randomized Phase 3 trial in…
NCT04965493 - Trial result Spotlight
Chronic myeloid leukemia
Asciminib deepens frontline molecular responses in East Asian CML-CP subgroup
Asciminib is a first-in-class allosteric BCR–ABL1 inhibitor that binds the ABL myristoyl pocket rather than the ATP-binding site targeted by standard TKIs. In the East Asian subgroup of the Phase 3 ASC4FIRST trial in…
NCT04971226 - Trial result Spotlight
Ovarian cancer
Rezatapopt (p53 Y220C reactivator) drives 46% ORR in heavily pretreated TP53 Y220C ovarian cancer
Rezatapopt is an oral, first-in-class small-molecule “p53 reactivator” that selectively binds mutant TP53 Y220C, stabilizes p53 in a wild-type–like conformation, and aims to restore tumor-suppressor function. In the…
NCT04585750 - Trial result Spotlight
Ovarian cancer
Fulvestrant + abemaciclib enables cytoreduction in unresectable LGSOC
Fulvestrant is an intramuscular selective estrogen receptor degrader, and abemaciclib is an oral CDK4/6 inhibitor targeting ER-driven cell-cycle signaling. In a pilot Phase 2 neoadjuvant study in advanced, initially…
NCT03531645 - Trial result Spotlight
Kidney cancer
Pembrolizumab + belzutifan (HIF-2α) improves adjuvant DFS in high-risk ccRCC—at a clear G3+ toxicity cost
Pembrolizumab is a PD-1 antibody and belzutifan is an oral hypoxia-inducible factor-2α (HIF-2α) inhibitor; in LITESPARK-022 (Phase 3, double-blind; NCT05239728), patients with resected clear-cell RCC at increased…
NCT05239728 - Trial result Spotlight
Non-small cell lung cancer
Ivonescimab (PD-1×VEGF bispecific) + pemetrexed/carboplatin extends OS after EGFR-TKI in NSCLC
Ivonescimab is a bispecific antibody that simultaneously targets PD-1 (checkpoint inhibition) and VEGF (anti-angiogenesis), aiming to pair immunotherapy with VEGF-pathway blockade in EGFR-variant nonsquamous NSCLC.…
NCT05184712 - Trial result Spotlight
Myeloproliferative neoplasms
Navitoclax (BCL-2/BCL-XL inhibitor) + ruxolitinib doubles Week-24 spleen responses in frontline myelofibrosis, with major cytopenias
Navitoclax (NAV), an oral BCL-2/BCL-XL inhibitor that can potentiate apoptosis but predictably worsens platelet counts via BCL-XL inhibition, was combined with the JAK1/2 inhibitor ruxolitinib (RUX) in the Phase 3…
NCT04472598
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.